Literature DB >> 11439329

Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells.

S Mohanam1, S L Jasti, S R Kondraganti, N Chandrasekar, S S Lakka, Y Kin, G N Fuller, A W Yung, A P Kyritsis, D H Dinh, W C Olivero, M Gujrati, F Ali-Osman, J S Rao.   

Abstract

Increases in abundance of cathepsin B transcript and protein correlate with increases in tumor grade and alterations in subcellular localization and activity of cathepsin B. The enzyme is able to degrade the components of the extracellular matrix (ECM) and activate other proteases capable of degrading ECM. To investigate the role played by this protease in the invasion of brain tumor cells, we transfected SNB19 human glioblastoma cells with a plasmid containing cathepsin B cDNA in antisense orientation. Control cells were transfected with vector alone. Clones expressing antisense cathepsin B cDNA exhibited significant reductions in cathepsin B mRNA, enzyme activity and protein compared to controls. Matrigel Invasion assay showed that the antisense-transfected cells had a markedly diminished invasiveness compared with controls. When tumor spheroids containing antisense transfected SNB19 cells expressing reduced cathepsin B were co-cultured with fetal rat brain aggregates, invasion of fetal rat brain aggregates was significantly reduced. Green Fluorescent Protein (GFP) expressing parental cells and antisense transfectants were generated for detection in mouse brain tissue without any post-chemical treatment. Intracerebral injection of SNB19 stable antisense transfectants resulted in reduced tumor formation in nude mice. These results strongly support a role for cathepsin B in the invasiveness of human glioblastoma cells and suggest cathepsin B antisense may prove useful in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439329     DOI: 10.1038/sj.onc.1204480

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas.

Authors:  Maode Wang; Jianjian Tang; Shouxun Liu; Daizo Yoshida; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  A QM/MM study of the binding of RAPTA ligands to cathepsin B.

Authors:  Antonella Ciancetta; Samuel Genheden; Ulf Ryde
Journal:  J Comput Aided Mol Des       Date:  2011-06-24       Impact factor: 3.686

Review 3.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

4.  Induction of cell death in neuroblastoma by inhibition of cathepsins B and L.

Authors:  Rita Colella; Guizhen Lu; Lisa Glazewski; Bruce Korant; Anjan Matlapudi; Matthew R England; Colin Craft; Christopher N Frantz; Robert W Mason
Journal:  Cancer Lett       Date:  2010-04-01       Impact factor: 8.679

5.  Prognostic and therapeutic relevance of cathepsin B in pediatric acute myeloid leukemia.

Authors:  Garima Pandey; Sameer Bakhshi; Manoj Kumar; Bhaskar Thakur; Prerna Jain; Punit Kaur; Shyam S Chauhan
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

6.  Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.

Authors:  Wan-Nan Chen; Jin-Yan Chen; Bo-Yan Jiao; Wan-Song Lin; Yun-Li Wu; Ling-Ling Liu; Xu Lin
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

7.  Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics.

Authors:  Maxime S Heroux; Marla A Chesnik; Brian D Halligan; Mona Al-Gizawiy; Jennifer M Connelly; Wade M Mueller; Scott D Rand; Elizabeth J Cochran; Peter S LaViolette; Mark G Malkin; Kathleen M Schmainda; Shama P Mirza
Journal:  Physiol Genomics       Date:  2014-05-06       Impact factor: 3.107

8.  Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells.

Authors:  Matteo Di Piazza; Carmen Mader; Karsten Geletneky; Marta Herrero Y Calle; Ekkehard Weber; Jörg Schlehofer; Laurent Deleu; Jean Rommelaere
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

9.  RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.

Authors:  Padmaja Tummalapalli; Daniel Spomar; Christopher S Gondi; William C Olivero; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  Int J Oncol       Date:  2007-11       Impact factor: 5.650

10.  Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.

Authors:  Jingxin Qiu; Lingbao Ai; Cheppail Ramachandran; Bing Yao; Suhasni Gopalakrishnan; C Robert Fields; Amber L Delmas; Lisa M Dyer; Steven J Melnick; Anthony T Yachnis; Philip H Schwartz; Howard A Fine; Kevin D Brown; Keith D Robertson
Journal:  Lab Invest       Date:  2008-07-07       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.